February 6, 2013 – Clinipace Worldwide, a digital clinical research organization (dCRO), announced today announced that the company has been listed at No. 36 on FORBES annual ranking of America’s Most Promising Companies — a list of 100 privately held, high-growth companies with bright futures. Clinipace is a portfolio company of Hatteras Venture Partners III.
January 31, 2013— Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and has also entered into a research collaboration agreement for posterior ocular diseases.
WASHINGTON – Hatteras Venture Partners of Durham, N.C. is the first licensee in the Early Stage Innovation Funds initiative, a part of the U.S. Small Business Administration’s (SBA) Small Business Investment Company (SBIC) capital investment program.
Durham, NC – Hatteras Venture Partners announced today the final closing of Hatteras Venture Partners IV (HVP IV) with $125 million in total capital. As a part of the final closing, HVP IV established a subsidiary fund, HVP IV SBIC, that is the first licensee of the US Small Business Administration’s (SBA) newly established Early Stage SBIC Program.